Literature DB >> 11013962

Clinical, biochemical, and pathological features in a patient with plasma cell dyscrasia and Fanconi syndrome.

G Lajoie1, R Leung, J M Bargman.   

Abstract

Multiple myeloma is associated with a wide array of renal diseases that include myeloma cast nephropathy, monoclonal immunoglobulin deposition disease, amyloidosis, cryoglobulinemia, tubular dysfunction, pyelonephritis, nephrocalcinosis, urate nephropathy, and infiltration by atypical plasma cells (or myeloma cells). Filtered immunoglobulin light chains may affect both the distal and, more frequently, the proximal tubule. Tubular abnormalities in patients with plasma cell dyscrasia may be more frequent than previously thought. A patient with a plasma cell dyscrasia is described, who presented with biochemical features consistent with Fanconi syndrome. Immunoelectron microscopy performed on the renal biopsy confirmed the presence of kappa light chain immunoglobulin in intracytoplasmic crystals in proximal tubular epithelial cells. This report is one of a few demonstrating the presence of light-chain immunoglobulin in intratubular crystals in a human renal biopsy obtained from a patient with a plasma cell dyscrasia and Fanconi syndrome.

Entities:  

Mesh:

Year:  2000        PMID: 11013962     DOI: 10.1080/01913120050176671

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  2 in total

1.  Systemic and rapidly progressive light-chain deposition disease initially presenting as tubulointerstitial nephritis.

Authors:  Satoko Takahashi; Jun Soma; Izaya Nakaya; Mayumi Yahata; Tsutomu Sakuma; Hiroshi Yaegashi; Akiyoshi Sato; Masaharu Wano; Hiroshi Sato
Journal:  CEN Case Rep       Date:  2012-07-19

2.  Acquired Fanconi syndrome secondary to light chain deposition disease associated with monoclonal gammopathy of renal significance: A case report.

Authors:  Haiyan Tu; Lijun Mou; Lina Zhu; Qifeng Jiang; Dave Schwinn Gao; Ying Hu
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.